Spruce Biosciences On March 16, Entered Termination Agreement With Kaken Pharmaceutical - SEC Filing

Reuters
2026.03.20 21:42
March 20 (Reuters) - SEC Filing: * SPRUCE BIOSCIENCES INC - ON MARCH 16, ENTERED TERMINATION AGREEMENT WITH KAKEN PHARMACEUTICAL - SEC FILING * SPRUCE BIOSCIENCES INC - COLLABORATION AGREEMENT WITH KAKEN PHARMACEUTICAL TO TERMINATE EFFECTIVE MARCH 31, 2026 - SEC FILING * SPRUCE BIOSCIENCES INC - ALL LICENSES & RIGHTS GRANTED BY CO TO KAKEN TO BE TERMINATDE; NO UNEARNED MILESTONE PAYMENTS OR ROYALTIES Source text: Further company coverage: (SPRB.O)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer